ResMed Inc. 🇺🇸
RMD • Healthcare • USA
💡 Institutional Quantitative Investment Thesis
High-quality compounder passing 8/9 fundamental checks. Strong balance sheet with Forward PER compression (20.9x vs 24.2x) and robust Free Cash Flow generation.
📊 Frequently Asked Questions & Related Moat Stocks
1. What is ResMed Inc. (RMD)'s Economic Moat Score in 2026?
In 2026, ResMed Inc. (RMD) holds a proprietary MoatPicks Economic Moat Score™ of 77.0/100 (Wide Economic Moat). This 12-point fundamental audit evaluates RMD's 61.6% gross margin, $939.2M free cash flow generation, +8.6% YoY revenue growth, and 0.4x Debt/EBITDA ratio. You can benchmark any stock's competitive durability interactively with our Economic Moat Score™ Checker.
2. Is RMD stock undervalued right now based on P/E and PEG ratio?
Yes — RMD currently screens as undervalued on a growth-adjusted basis with a Peter Lynch PEG ratio of 1.16x (below the 1.2x GARP threshold) and a Forward P/E of 20.9x. At a share price of $252.86, investors can stress-test RMD's fair value using the MoatPicks Economic Moat Score™ Checker and FIRE compounding calculators. Model how compounding RMD fits your long-term retirement target in our FIRE Financial Independence Calculator.
3. Which superinvestors and 13F hedge funds own RMD stock?
ResMed Inc. (RMD) is actively monitored across our 25 tracked 13F superinvestor portfolios and institutional quality screens. Institutional capital focuses on RMD's 61.6% gross margin, $939.2M free cash flow, and 0.4x Debt/EBITDA balance sheet.